
Aridis Pharmaceuticals ARDS
Quarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Total Current Liabilities 2011-2026 | ARDS
Annual Total Current Liabilities Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.9 M | 33.3 M | 22.4 M | 19.3 M | 5.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.9 M | 5.3 M | 23.5 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alector
ALEC
|
69.5 M | $ 2.08 | -14.4 % | $ 214 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Altimmune
ALT
|
10.5 M | $ 4.2 | -2.67 % | $ 298 M | ||
|
Apellis Pharmaceuticals
APLS
|
324 M | $ 20.24 | -3.44 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 0.8 | 1.87 % | $ 4.36 M | ||
|
Aprea Therapeutics
APRE
|
4.39 M | $ 0.88 | -3.72 % | $ 3.18 M | ||
|
Aptevo Therapeutics
APVO
|
6.21 M | $ 7.2 | -1.64 % | $ 1.99 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Aquestive Therapeutics
AQST
|
18.9 M | $ 4.1 | 2.37 % | $ 356 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Arcturus Therapeutics Holdings
ARCT
|
65.5 M | $ 8.35 | 1.46 % | $ 225 M | ||
|
Ardelyx
ARDX
|
88.6 M | $ 6.37 | -2.75 % | $ 1.54 B | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Armata Pharmaceuticals
ARMP
|
16.5 M | $ 10.91 | 1.58 % | $ 394 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 25.33 | -6.1 % | $ 3.22 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Artelo Biosciences
ARTL
|
4.04 M | $ 1.15 | -3.36 % | $ 2.32 M | ||
|
Arvinas
ARVN
|
142 M | $ 12.97 | -2.3 % | $ 920 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
195 M | $ 61.74 | -2.42 % | $ 8.26 B | ||
|
Actinium Pharmaceuticals
ATNM
|
8.15 M | $ 1.17 | -0.85 % | $ 35.2 M | ||
|
Atossa Therapeutics
ATOS
|
5.24 M | $ 4.39 | -0.9 % | $ 553 M | ||
|
Atara Biotherapeutics
ATRA
|
135 M | $ 5.01 | -7.47 % | $ 37.5 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
93.7 M | $ 14.14 | -0.21 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.68 | -1.75 % | $ 429 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Atea Pharmaceuticals
AVIR
|
18.6 M | $ 4.69 | 0.21 % | $ 395 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
5.04 M | $ 4.54 | 2.44 % | $ 387 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Axon Enterprise
AXON
|
1.68 B | $ 570.5 | 5.18 % | $ 43.2 B | ||
|
Axsome Therapeutics
AXSM
|
379 M | $ 162.28 | -0.98 % | $ 8.07 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.56 | -0.58 % | $ 16.1 M | ||
|
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B |